ReviewVaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience
Research highlights
▶ Vaccine preventable diseases remain a severe burden in aged population, and foremost amongst them is influenza. ▶ While it is widely believed that influenza vaccination safes many lives, the exact magnitude of its benefits is still debate in the aged population, because: ▶ the accurate assessment of vaccine benefits is still fraught with considerable methodological and epidemiological challenges, ▶ Pre-immunization antibody levels severely influence the interpretation of vaccine response, HAI-antibody titres cannot be used as gold standard against which to measure vaccine efficacy/effectiveness ▶ while immunosenescence is undoubtedly one of the most important phenomenon adversely influencing vaccine response, methods identifying and measuring it and for understanding its implications for vaccine response still require further evaluation.
Introduction
Vaccine preventable diseases (VPDs) remain a severe burden in adult populations of developed countries (Michel and Lang, 2011). In the United States, they account for more than 70,000 deaths per year in these populations compared with 200 deaths in children (Poland et al., 2009). Aside from a 350-fold increased likelihood of death, VPDs are also associated with an age-related increase in serious adverse health events leading to hospitalization, debilitating complications and/or death (Michel and Lang, 2011). Deleterious changes in the adaptive immune system mainly associated with advancing age are major contributors to a less than optimal response either to the vaccination or to infectious agents (Aspinall and Goronzy, 2010).
Foremost amongst VPDs is influenza. Worldwide estimates indicate that influenza infections cause 3–5 million of severe cases per year resulting in 250,000–350,000 deaths (Influenza, 2008). In the European Union, between 40,000 and 220,000 deaths per year have been attributed to infection by influenza (Seasonal Human Influenza and Vaccination, 2010). The highest prevalence mainly occurs amongst older adults especially those with chronic medical conditions or immunological disorders, resulting in increased mortality in these high risk groups (World Health Organization, 2005). However, mortality is just the tip of the iceberg in terms of disease burden, as it can also act as a trigger for functional decline leading to disability in some aged individuals (Monto et al., 2009, McElhaney, 2005, Greenberg and Piedra, 2004, Gavazzi and Krause, 2002). Such outcomes represent a considerable economic burden amounting to $87 billion each year in the United States (Molinari et al., 2007). While it is widely believed that influenza vaccination saves many lives, prompting the widespread use of trivalent inactivated influenza vaccine (TIVs – 300 million doses produced each year) the exact magnitude of the benefit of the current immunization strategy in the aged population is still controversial (Jefferson, 2006, Fireman et al., 2009, Jackson et al., 2006a, Jackson et al., 2006b, Jackson et al., 2008, Simonsen et al., 2007, Simonsen et al., 2009). This review will aim to examine how effective current influenza-vaccine strategies are in aged adults and analyse which are the most important factors modulating the interpretation of study results in this population. Furthermore, consideration will be given to how immune factors influence the measurement of vaccine efficacy/effectiveness. This review will conclude with possible strategies to improve the ability of the senescent immune system to respond to vaccination.
Section snippets
Is current influenza vaccine actually effective in aged individuals?
The current TIVs contain 15 μg of hemagglutinine (HA) of each of the three influenza strains (A/H1N1, A/H3N2 and influenza B). Humoral anti-HA antibody response is used as a surrogate marker for vaccine efficacy (Fiore et al., 2008). To assist in the interpretation of influenza vaccine immunogenicity, the Committee for Proprietary Medicinal Products (CPMP) describes a satisfactory HA inhibition (HAI) by serum anti-HA antibody response in the aged population (Note for Guidance on Harmonization of
Do pre-vaccination HA-antibody titres influence the vaccine response?
Most adults have pre-existing levels of antibody because of prior influenza infection and/or flu vaccination but this will vary in specificity depending on the age of the individual (Sasaki et al., 2008). Thus, young adults and elderly differ markedly for A/H1N1 strains (circulating between 1918 and 1957 and reintroduced in 1976), but are more similar for A/H3N2 strains (circulating since 1968). Older individuals with siblings infected during the influenza outbreak of 1918 possess highly
Is immunosenescence a quantifiable disorder?
Since the single preceding event in all cases of immunosenescence is thymic involution, can we identify a specific thymic rate of output which is linked to a state of immunosenescence? Studies to identify recent thymic emigrants (RTEs) have shown that the optimal means possibly uses a mixture of molecular and phenotypic techniques. Molecular techniques include PCR based assays of populations of cells for their content of signal joint T-cell receptor gene excision circles (sj-TREC) which are
Conclusion
Influenza virus infection remains a major public health concern across the world and the overall body of evidence nevertheless suggests that influenza vaccination is also beneficial for aged individuals. However, this review demonstrates that the achievement of an accurate assessment of vaccine benefits is still fraught with considerable methodological and epidemiological challenges. Of course, designing new randomized placebo-controlled trials could be a solution but this would be also an
Conflict of interest
None is declared for this manuscript.
References (110)
- et al.
Immune senescence
Curr. Opin. Immunol.
(2010) - et al.
Immunity in the elderly: the role of the thymus
J. Comp. Pathol.
(2010) - et al.
Antibody induction by influenza vaccines in the elderly: a review of the literature
Vaccine
(1989) - et al.
Jha A Do Medicare patients with disabilities receive preventive services? A population based study
Arch. Phys. Med. Rehabil.
(1999) - et al.
FluBlok a next generation influenza vaccine manufactured in insect cells
Biologicals
(2009) - et al.
The virosomal influenza vaccine Invivac: immunogeneicity and tolerability compared to adjuvanted influenza vaccine (Fluad) in elderly subjects
Vaccine
(2006) - et al.
LAIV Elderly Study Trial Network. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older
Vaccine
(2009) - et al.
Epidermal DNA vaccine for influenza is immunogenic in humans
Vaccine
(2006) Telomerase induction in T cells: a cure for aging and disease?
Exp. Gerontol.
(2007)- et al.
Antibody quantity versus quality after influenza vaccination
Vaccine
(2009)
Ageing and infection
Lancet Infect. Dis.
Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when co-administered with a heat-labile enterotoxin (LT) adjuvant patch
Vaccine
Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells
Mech. Ageing Dev.
Immune response to influenza vaccination in community-dwelling Chinese elderly persons
Vaccine
Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study
Lancet
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
Lancet
Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults
Vaccine
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterogeneous booster vaccination: an open non-randomised extension of a double-blind randomised primary study
Vaccine
Influenza vaccination health impact and cost effectiveness among adults aged 50–64 and 65 and older
Am. J. Prev. Med.
The unmet need in the elderly: designing new influenza vaccines for older adults
Vaccine
Antibody response to whole-virus and split-virus influenza vaccines in successful ageing
Vaccine
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
Lancet
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
Vaccine
The annual impact of seasonal influenza in the US: measuring disease burden and costs
Vaccine
Influenza control in the 21st century: optimizing protection for older adults
Vaccine
Immunomodulating effect of influenza vaccination in the elderly differing in health status
Exp. Gerontol.
New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among senior
J. Clin. Epidemiol.
Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy
Vaccine
Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics
Vaccine
In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant
Vaccine
Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised-trial
Vaccine
Mortality benefits of influenza vaccination in elderly people: an ongoing controversy
Lancet Infect. Dis.
Influenza vaccination and mortality benefits: new insights, new opportunity
Vaccine
No immune risk profile among individuals who reach 100 years of age findings from the Swedish NONA immune longitudinal study
Exp. Gerontol.
Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination—an impact of immunosenescence
Vaccine
A simple method for the measurement of sjTREC levels in blood
Mech. Ageing Dev.
Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor
J. Virol.
Immune response to influenza vaccination in an elderly population
J. Clin. Immunol.
Influenza revaccination of elderly travellers: antibody response to single influenza vaccination and revaccination at 12 weeks
J. Infect. Dis.
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects
Vaccine
Recommendation of the Advisory Committee on Immunization Practices (ACIP)
MMWR Morb. Mortal. Wkly. Rep.
Influenza vaccines provide diminished protection but are cost-saving in older adults
J. Intern. Med.
Influenza vaccination and warfarin anticoagulation: a comparison of subcutaneous and intramuscular routes of administration in elderly men
Pharmacotherapy
Role of T lymphocyte replicative senescence in vaccine efficacy
Vaccine
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older
J. Infect. Dis.
Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes
J. Immunol.
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008
MMWR Morb. Mortal. Wkly. Rep.
Influenza vaccination and mortality: differentiating vaccine effects from bias
Am. J. Epidemiol.
Immunosenescence and vaccination in nursing home
Clin. Infect. Dis.
Antibody response to influenza vaccine in the elderly: a quantitative review
Vaccine
Cited by (54)
Immunosenescence in multiple sclerosis: the identification of new therapeutic targets
2021, Autoimmunity ReviewsEffectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies
2017, The Lancet Respiratory MedicineCitation Excerpt :The ability of inactivated seasonal influenza vaccines to reduce the risk of influenza and influenza-related complications—referred to as influenza vaccine effectiveness—in the high-risk group of elderly people varies significantly from season to season depending on factors such as intensity of influenza virus activity, interval between vaccination and symptom onset, vaccine match to the circulating viruses, and influenza virus types and subtypes.1–4
Tetanus risk assessment in the older outpatients: Usefulness of the "Tétanos Quick Stick<sup>®"</sup>?
2015, Revue de Medecine InterneInfluenza vaccination. Seasonal flu or epidemic
2014, VacunasSeasonal influenza surveillance: Observational study on the 2017–2018 season with predominant B influenza virus circulation
2019, VacunasCitation Excerpt :Summary of the main features of the 2017–2018 influenza epidemic season are shown in Table 4. Influenza virus infection is still a topic of great relevance to global health.1 The high percentage of hospitalizations (65.1%) and mortality in the age group of over 64 (17.5%), especially those over the age of 80, where mortality is higher (33.3%), reflects the increase in the life expectancy of the population.